Detalles de la búsqueda
1.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34758069
2.
Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
Eur J Haematol
; 112(6): 927-937, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38342972
3.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38693677
4.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol
; 102(11): 3083-3090, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358640
5.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
6.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
N Engl J Med
; 377(14): 1331-1344, 2017 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28976863
7.
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Eur J Haematol
; 105(2): 116-125, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32155662
8.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica
; 104(5): 955-962, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514803
9.
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Ann Hematol
; 96(11): 1857-1866, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28905189
10.
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 17(7): 928-942, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27216274
11.
Palliative treatment of colorectal cancer with secondary metastasis resection in Germany - impact of the multidisciplinary treatment approach on prognosis and cost: the Northern Bavaria IVOPAK I Project.
Oncology
; 88(2): 103-21, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25341688
12.
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Ann Hematol
; 93(7): 1167-76, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24658964
13.
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood
; 116(19): 3743-50, 2010 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20628153
14.
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Eur J Haematol
; 88(3): 260-8, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22023452
15.
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Br J Haematol
; 153(2): 212-21, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21375521
16.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med
; 359(9): 906-17, 2008 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-18753647
17.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Eur J Haematol
; 86(1): 23-31, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20874823
18.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Eur J Haematol
; 86(5): 372-84, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21366694
19.
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
Hemasphere
; 5(7): e600, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34179697
20.
Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany.
Onkologie
; 33(1-2): 39-44, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20164660